| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
(2-Hydroxypropyl)-β-cyclodextrin is a cyclodextrin oligosaccharide that has been widely used drug delivery vehicle to improve the aqueous solubility, stability and bioavailability of chemical compounds.
| ln Vitro |
Treatment of cells with HP-β-CD activates the transcription factor EB, a fundamental regulator of lysosomal activity and autophagy, and promotes autophagic clearance [1]. HP-β-CD therapy lowered intracellular cholesterol and effectively suppressed leukemic cell proliferation through G2/M cell cycle arrest and death. After 72 hours of exposure, the IC50 values of HP-β-CD were in the range of 3.86-10.09 mM. HP-β-CD also displayed anticancer effects on CML cells bearing the T315I BCR-ABL mutation (conferring resistance to most ABL tyrosine kinase inhibitors) and hypoxia-adapted CML cells with leukemic stem cell features. In addition, the colony-forming ability of human primary AML and CML cells is reduced by HP-β-CD [2].
|
|---|---|
| ln Vivo |
Because cells generated from patients with lysosomal storage illnesses have reduced activity of the lysosomal autophagy system, HP-β-CD treatment increases transcription factor EB-mediated clearance of proteolipid aggregates and accumulates [1]. Leukemia mice models can have a much higher survival rate when HP-β-CD is injected intraperitoneally. Mice given HP-β-CD systemically did not exhibit any overt negative effects [2].
|
| References |
[1]. Song W, et al. 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem. 2014 Apr 4;289(14):10211-22.
[2]. Yokoo M, et al. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 2015 Nov 4;10(11):e0141946 |
| Molecular Formula |
C63H12O42
|
|---|---|
| Molecular Weight |
1541.54
|
| CAS # |
128446-35-5
|
| Related CAS # |
128446-35-5 ;107745-73-3;
|
| SMILES |
CO[C@@H]1[C@H](O[R])[C@@H](O)[C@H](C)[C@@H](CO[R])O1.[CD2]CC(O)C.[R].[7].[R=H or]
|
| Synonyms |
Hydroxypropyl betadex (2-Hydroxypropyl)-β-cyclodextrinHydroxypropyl-β-cyclodextrin HP-β-CD
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL
H2O : ~50 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). Solubility in Formulation 5: 200 mg/mL (Infinity mM) in Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6487 mL | 3.2435 mL | 6.4870 mL | |
| 5 mM | 0.1297 mL | 0.6487 mL | 1.2974 mL | |
| 10 mM | 0.0649 mL | 0.3244 mL | 0.6487 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA